SEC Form 4 · accession 0001209191-16-095842
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Feb 2, 2016
Accepted (ET)
Feb 4, 2016 · 6:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 2, 2016 | A | 53,817 | $0.01 | A | 271,719 | D | |
| Common StockF3,F4 | Feb 3, 2016 | S | 4,200 | $89.91 | D | 267,519 | D | |
| Common StockF4,F5 | Feb 3, 2016 | S | 3,700 | $91.01 | D | 263,819 | D | |
| Common StockF4,F6 | Feb 3, 2016 | S | 900 | $91.96 | D | 262,919 | D | |
| Common StockF4,F7 | Feb 3, 2016 | S | 1,034 | $92.87 | D | 261,885 | D | |
| Common Stock | holding | — | — | — | 440 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $91.05 | Feb 2, 2016 | A | 107,276 | A | — | Feb 1, 2026 | Common Stock | 107,276 | 107,276 | D |
Explanation of responses
- F1Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019.
- F2Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- F3Open market sales reported on this line occurred at a weighted average price of $89.91 (range $89.31 to $90.27).
- F4Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F5Open market sales reported on this line occurred at a weighted average price of $91.01 (range $90.37 to $91.33).
- F6Open market sales reported on this line occurred at a weighted average price of $91.96 (range $91.40 to $92.37).
- F7Open market sales reported on this line occurred at a weighted average price of $92.87 (range $92.50 to $93.11).
- F8The option vests in 16 quarterly installments from 02/02/2016.